课题基金 / 基金详情

Novel Therapeutics for Timothy Syndrome and Related Cardiac Channelopathy

Novel Therapeutics for Timothy Syndrome and Related Cardiac Channelopathy
蒂莫西综合征和相关心脏通道病变的新疗法
批准号:
10911506
负责人:
Masayuki Yazawa
金额:
$70.94万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-01 至 2026-05-31

项目摘要

项目成果

Masayuki Yazawa的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary: Calcium channel dysfunction in excitable cells, such as cardiomyocytes, neurons and beta-cells, induces lethal cardiac arrhythmias such as Timothy syndrome, a severe form of genetic long QT syndrome, and also psychiatric disorders such as autism and schizophrenia as well as abnormal insulin secretion, respectively. In preliminary experiments using pharmaceutical approach, we found that activation of Sigma 1 receptor using its agonists could alleviate the cellular phenotypes in human induced pluripotent stem cell (iPSC) and mouse models of the genetic disease. The goal of this study is to examine the molecular mechanism underlying the beneficial effect of Sigma 1 receptor activation on the phenotypes in ion channel regulation, action potentials, mitochondrial function and gene expression in the genetic diseases. We will use human iPSC and rodent models to accomplish our goal. In addition, we will design and synthesize new small molecules to develop novel Sigma 1 receptor agonists that are more suitable for each phenotype in the genetic disease, taking advantage of our expertise in pharmaceutical science and medicinal chemistry. Therefore, our translational study will provide new opportunity of drug development for genetic syndromic disorders including cardiac arrhythmia, autism and abnormal insulin secretion.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Therapeutics for Long QT Syndrome
Novel Therapeutics for Long QT Syndrome
Molecular mechanisms underlying cardiac sodium channelopathy
Molecular mechanisms underlying cardiac sodium channelopathy
海外基金